McComsey GA, et al. - Researchers here focused on the bone mineral density (BMD) loss, a risk factor for osteoporosis, attributable to HIV infection and antiretroviral therapy (ART), including regimens containing tenofovir disoproxil fumarate. Compared with tenofovir-based three-drug regimens, switch to dolutegravir with rilpivirine was associated with significant improvement in BMD and bone turnover markers. Thereby suggesting it to be a robust option for preserving bone health while continuing suppressive ART.